EHRA 2023: Late-Breaking Science Video Collection
Published: 18 April 2023
6m 49sPart 1 | Session 3 MANIFEST-PF: Real-world Experience of PFA in Commercial Practice
2m 38sPart 1 | Session 5 TEMPO-HCM: Extended ECG Monitoring in HCM
3m 37sPart 1 | Session 6 Conformable PVI Catheter for Pulmonary Vein Isolation
3m 54sPart 1 | Session 7 BRUGADA Randomized: Epidcardial Ablation to Prevent Sudden Death
6m 25sPart 2 | Session 1 5 Trials That Will Change Your Practice With Dr Sohaib
6m 24sPart 2 | Session 2 4 Trials That Will Change Your Practice With Dr Di Biase
54sPart 3 | Session 1 Dr Bergonti: Pulsed-Field Ablation & Reasons to Research
1m 52sPart 3 | Session 2 Dr Bruce Wilkoff: Therapy Morbidity and Advice to Young Researchers
31sPart 3 | Session 3 Dr Carlo Pappone: Advice to Early-Career Electrophysiologists
28sPart 3 | Session 4 Dr Juan Caro Codon: Building a Team For Success
4m 23sPart 1 | Session 1 POTTER: Oesophageal Fistulae in Catheter Ablation Patients Roland R Tilz
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice.
More from this programme
In these concise overviews, selected faculty provide their thoughts on the most impactful trials from EHRA 2023.
Behind the Heart
Watch our Behind the Heart series to learn more about the personal perspectives of the investigators behind top trials in cardiovascular science.
About the episode
In AdaptResponse, investigators studied the hypothesis that cardiac resynchronization therapy (CRT) devices which utilised AdaptivCRT® (aCRT) algorithm (Medtronic) had better prognosis in patients with normal atrioventricular conduction and left bundle branch block when directly compared with patients who had received standard CRT devices.
1. What was the reasoning behind this study?
2. What was the patient population and study design?
3. What are the main findings?
4. How should these findings be implemented in clinical practice?
5. What are the next steps?
Recorded on-site at EHRA 2023, Barcelona.
Editor: Jordan Rance
Dr Bruce Wilkoff is the Director of Cardiac Pacing and Tachyarrhythmia Devices and a staff cardiologist at Cleveland Clinic Main Campus, Cleveland, US.
Dr Wilkoff is also a Professor of Medicine at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. He is board-certified in internal medicine, cardiovascular disease and a Certified Cardiac Device Specialist.
His clinical interests include abnormal heart rhythms, bradyarrhythmias, sudden cardiac death, lead extraction, implantable cardioverter defibrillator and more.